Gait Speed and All‐Cause Mortality in Whole‐Spectrum Chronic Kidney Disease: A Systematic Review and Meta‐Analysis Included 6217 Participants
Open Access
- 24 February 2025
- journal article
- research article
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 16 (1) , e13739
Abstract
Background: The quantitative relationship between gait speed and mortality risk in patients with chronic kidney disease remains unclear. This study aimed to conduct a meta‐analysis to estimate the risk of mortality associated with gait speed in chronic kidney disease (CKD) patients. Methods: Relevant studies published were identified through literature searches using Embase, PubMed and Web of Science. Prospective cohort studies of adult CKD patients that examined the relationship between gait speed and mortality were included. Random effects meta‐analyses based on restricted maximum likelihood to were used to calculate relative risk (RR) and 95% confidence interval (95% CI). The results of meta‐analyses were assessed using Grading of Recommendations, Assessment, Development and Evaluation framework. Results: Seventeen prospective cohort studies involving 6217 CKD patients (mean age range: 51.6–81.85 years; 44.3%–84% male) were included. Pooled analysis of 12 studies ( n = 4233) showed that lower gait speed was associated with a higher risk of all‐cause mortality compared to higher gait speed (RR = 2.138; 95% CI: 1.794–2.548; p < 0.001; I 2 = 16.0%; high‐certainty evidence) in CKD patients. Dose–response meta‐analysis of 6 studies ( n = 1650) revealed that each 0.1 m/s increase in gait speed was associated with a 25.7% lower risk of all‐cause mortality (RR = 0.743; 95% CI: 0.580–0.955; p = 0.018; I 2 = 45.0%; high‐certainty evidence). Conclusions: Slower gait speed is a strong predictor of all‐cause mortality in CKD patients, including those undergoing dialysis or kidney transplantation. Gait speed assessment should be incorporated into routine clinical evaluations to identify high‐risk patients and guide interventions aimed at improving physical function and survival outcomes. Trial Registration: PROSPERO registration number: CRD42022340135Keywords
Funding Information
- Shanghai Municipal Hospital Development Center (SHDC2022CRD003)
- Shanghai Municipal Hospital Development Center (SHDC2022CRW006)
- Shanghai University of Traditional Chinese Medicine (602059D)
This publication has 59 references indexed in Scilit:
- Meta-Analysis for Linear and Nonlinear Dose-Response Relations: Examples, an Evaluation of Approximations, and SoftwareAmerican Journal of Epidemiology, 2011
- Gait Speed and Survival in Older AdultsJAMA, 2011
- Objectively measured physical capability levels and mortality: systematic review and meta-analysisBMJ, 2010
- White Paper: “Walking Speed: the Sixth Vital Sign”Journal of Geriatric Physical Therapy, 2009
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- Facilitating meta‐analyses by deriving relative effect and precision estimates for alternative comparisons from a set of estimates presented by exposure level or disease categoryStatistics in Medicine, 2007
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- Frailty in Older Adults: Evidence for a PhenotypeThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2001
- Meta-analysis of Observational Studies in EpidemiologyA Proposal for ReportingJAMA, 2000
- Bias in meta-analysis detected by a simple, graphical testBMJ, 1997